Hypertension

Last updated: April 18, 2022
Sponsor: Alnylam Pharmaceuticals
Overall Status: Active - Recruiting

Phase

2

Condition

High Blood Pressure (Hypertension)

Treatment

N/A

Clinical Study ID

TX290671
ALN-AGT01-003
  • Ages 18-75
  • All Genders

Study Summary

The purpose of this study is to evaluate the effect of zilebesiran on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of zilebesiran as add-on therapy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 18 to 75 years.
  • Office SBP at Screening as follows: a.) ≥155 mmHg and ≤180 mmHg for patients with untreated hypertension; b.) ≥145 mmHg and ≤180 mmHg for patients on antihypertensive medications; c.) 24-hour mean SBP >130 mmHg and ≤160 mmHg by ABPM after at least 4 weeks of run-in on protocol-specified background antihypertensive medication

Exclusion

Exclusion Criteria:

  • Secondary hypertension, orthostatic hypotension
  • Received an investigational agent within the last 30 days
  • Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus, newly diagnosed Type 2 diabetes mellitus
  • History of any cardiovascular event within 6 months prior to randomization
  • History of intolerance to SC injection(s)

Study Design

Study Start date:
January 14, 2022
Estimated Completion Date:

Study Description

  • Condition: Hypertension
  • Clinical Trial Identifier: NCT05103332
  • Sponsor: Alnylam Pharmaceuticals

Looking for participants within a 30 mile radius of the study site.

Connect with a study center

  • Clinical Research of South Florida

    Coral Gables, Florida 33134
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.